Skip to content

Tegoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori -Non-inferiority, Multicenter, Randomized controlled study

Tegoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori -Non-inferiority, Multicenter, Randomized controlled study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400094542
Enrollment
Unknown
Registered
2024-12-24
Start date
2024-06-24
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

Group A:Tegoprazan combined with amoxicillin, 14 days
Group B:Tegoprazan combined with amoxicillin, 10days
Group C:Standard quadruple therapy

Sponsors

The Second Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Between the ages of 18 and 65; 2.The carbon-13 breath test was positive in the past 1 week;

Exclusion criteria

Exclusion criteria: 1.Patients who have been treated with H. pylori in the past; 2.Previous history of tumors, hepatic and renal insufficiency, HIV infection, hematologic or neurological disorders; 3.Patients who have used bismuth or antibiotics within 28 days, pregnant, lactating women, allergies to or history of allergies to the study drug or component drugs; 4.History of gastric surgery; 5.Non-compliance with study treatment or lack of informed consent;

Design outcomes

Primary

MeasureTime frame
Hp eradication rate;

Secondary

MeasureTime frame
Incidence, severity, and frequency of adverse reactions;

Countries

China

Contacts

Public ContactLyu Lin

The Second Affiliated Hospital of Chongqing Medical University

lin-miaomiao@126.com+86 13677647122

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026